BACKGROUND: Analysis of the impact of risk factors on survival in patients with oropharyngeal squamous cell carcinoma (OPSCC) treated by primary intensity-modulated radiotherapy (IMRT). METHODS: One hundred forty patients were included with tissue microarray (TMA) construction and immunohistochemical analysis in 124 patients (87%). RESULTS: Survival analysis of patients classified into 3 risk categories according to an algorithm based on p16, smoking, T classification, and N classification revealed significant differences with a low, intermediate, and high-risk group. There was a significant impact of p53 expression as surrogate marker for smoking on outcome. In multivariate analysis, p16-positivity was a positive predictor and alcohol as well as N classification was a negative predictor for survival. The algorithm was modified based on alcohol instead of smoking with even more significant differences between the groups. CONCLUSIONS: A risk model based on multiple factors instead of p16 as single marker can define different risk groups to select patients for treatment deintensification in future prospective clinical trials.
BACKGROUND: Analysis of the impact of risk factors on survival in patients with oropharyngeal squamous cell carcinoma (OPSCC) treated by primary intensity-modulated radiotherapy (IMRT). METHODS: One hundred forty patients were included with tissue microarray (TMA) construction and immunohistochemical analysis in 124 patients (87%). RESULTS: Survival analysis of patients classified into 3 risk categories according to an algorithm based on p16, smoking, T classification, and N classification revealed significant differences with a low, intermediate, and high-risk group. There was a significant impact of p53 expression as surrogate marker for smoking on outcome. In multivariate analysis, p16-positivity was a positive predictor and alcohol as well as N classification was a negative predictor for survival. The algorithm was modified based on alcohol instead of smoking with even more significant differences between the groups. CONCLUSIONS: A risk model based on multiple factors instead of p16 as single marker can define different risk groups to select patients for treatment deintensification in future prospective clinical trials.
Authors: Saad Maqsood; Michael B Jameson; Charles De Groot; Cristian Hartopeanu; Nur Azri Bin Haji Mohd Yasin; Ziad Thotathil Journal: Cancer Rep (Hoboken) Date: 2018-04-10
Authors: Vlad C Sandulache; John Hamblin; Syeling Lai; Todd Pezzi; Heath D Skinner; Numan A Khan; Shayan M Dioun; Christine Hartman; Jennifer Kramer; Elizabeth Chiao; Xiaodong Zhou; Jose P Zevallos Journal: Head Neck Date: 2015-07-04 Impact factor: 3.147
Authors: B Pajares; L Perez-Villa; J M Trigo; M D Toledo; M Alvarez; B Jimenez; J A Medina; V de Luque; J M Jerez; E Alba Journal: Clin Transl Oncol Date: 2013-11-06 Impact factor: 3.405
Authors: R Maquieira; S K Haerle; G F Huber; A Soltermann; S R Haile; S J Stoeckli; Martina A Broglie Journal: Eur Arch Otorhinolaryngol Date: 2015-06-10 Impact factor: 2.503
Authors: Si-Young Kiessling; Martina Anja Broglie; Alex Soltermann; Gerhard Frank Huber; Sandro Johannes Stoeckli Journal: Laryngoscope Investig Otolaryngol Date: 2018-08-09